<?xml version='1.0' encoding='utf-8'?>
<document id="29768713"><sentence text="Clinical Drug-Drug Interaction Potential of BFE1224, Prodrug of Antifungal Ravuconazole, Using Two Types of Cocktails in Healthy Subjects."><entity charOffset="75-87" id="DDI-PubMed.29768713.s1.e0" text="Ravuconazole" /></sentence><sentence text="BFE1224, prodrug of ravuconazole, is a novel, once-daily, oral, triazole antifungal drug, and currently in development for the treatment of onychomycosis"><entity charOffset="20-32" id="DDI-PubMed.29768713.s2.e0" text="ravuconazole" /><entity charOffset="64-72" id="DDI-PubMed.29768713.s2.e1" text="triazole" /><pair ddi="false" e1="DDI-PubMed.29768713.s2.e0" e2="DDI-PubMed.29768713.s2.e0" /><pair ddi="false" e1="DDI-PubMed.29768713.s2.e0" e2="DDI-PubMed.29768713.s2.e1" /></sentence><sentence text=" The clinical drug-drug interaction (DDI) potential of BFE1224 with cytochrome P450 (CYP) and transporter was assessed by using two types of cocktails in healthy subjects in separate clinical studies" /><sentence text=" The CYP and transporter cocktails consisted of caffeine/tolbutamide/omeprazole/dextromethorphan/midazolam used in study 1 and digoxin/rosuvastatin used in study 2"><entity charOffset="48-56" id="DDI-PubMed.29768713.s4.e0" text="caffeine" /><entity charOffset="57-68" id="DDI-PubMed.29768713.s4.e1" text="tolbutamide" /><entity charOffset="69-79" id="DDI-PubMed.29768713.s4.e2" text="omeprazole" /><entity charOffset="80-96" id="DDI-PubMed.29768713.s4.e3" text="dextromethorphan" /><entity charOffset="97-106" id="DDI-PubMed.29768713.s4.e4" text="midazolam" /><entity charOffset="127-134" id="DDI-PubMed.29768713.s4.e5" text="digoxin" /><entity charOffset="135-147" id="DDI-PubMed.29768713.s4.e6" text="rosuvastatin" /><pair ddi="false" e1="DDI-PubMed.29768713.s4.e0" e2="DDI-PubMed.29768713.s4.e0" /><pair ddi="false" e1="DDI-PubMed.29768713.s4.e0" e2="DDI-PubMed.29768713.s4.e1" /><pair ddi="false" e1="DDI-PubMed.29768713.s4.e0" e2="DDI-PubMed.29768713.s4.e2" /><pair ddi="false" e1="DDI-PubMed.29768713.s4.e0" e2="DDI-PubMed.29768713.s4.e3" /><pair ddi="false" e1="DDI-PubMed.29768713.s4.e0" e2="DDI-PubMed.29768713.s4.e4" /><pair ddi="false" e1="DDI-PubMed.29768713.s4.e0" e2="DDI-PubMed.29768713.s4.e5" /><pair ddi="false" e1="DDI-PubMed.29768713.s4.e0" e2="DDI-PubMed.29768713.s4.e6" /><pair ddi="false" e1="DDI-PubMed.29768713.s4.e1" e2="DDI-PubMed.29768713.s4.e1" /><pair ddi="false" e1="DDI-PubMed.29768713.s4.e1" e2="DDI-PubMed.29768713.s4.e2" /><pair ddi="false" e1="DDI-PubMed.29768713.s4.e1" e2="DDI-PubMed.29768713.s4.e3" /><pair ddi="false" e1="DDI-PubMed.29768713.s4.e1" e2="DDI-PubMed.29768713.s4.e4" /><pair ddi="false" e1="DDI-PubMed.29768713.s4.e1" e2="DDI-PubMed.29768713.s4.e5" /><pair ddi="false" e1="DDI-PubMed.29768713.s4.e1" e2="DDI-PubMed.29768713.s4.e6" /><pair ddi="false" e1="DDI-PubMed.29768713.s4.e2" e2="DDI-PubMed.29768713.s4.e2" /><pair ddi="false" e1="DDI-PubMed.29768713.s4.e2" e2="DDI-PubMed.29768713.s4.e3" /><pair ddi="false" e1="DDI-PubMed.29768713.s4.e2" e2="DDI-PubMed.29768713.s4.e4" /><pair ddi="false" e1="DDI-PubMed.29768713.s4.e2" e2="DDI-PubMed.29768713.s4.e5" /><pair ddi="false" e1="DDI-PubMed.29768713.s4.e2" e2="DDI-PubMed.29768713.s4.e6" /><pair ddi="false" e1="DDI-PubMed.29768713.s4.e3" e2="DDI-PubMed.29768713.s4.e3" /><pair ddi="false" e1="DDI-PubMed.29768713.s4.e3" e2="DDI-PubMed.29768713.s4.e4" /><pair ddi="false" e1="DDI-PubMed.29768713.s4.e3" e2="DDI-PubMed.29768713.s4.e5" /><pair ddi="false" e1="DDI-PubMed.29768713.s4.e3" e2="DDI-PubMed.29768713.s4.e6" /><pair ddi="false" e1="DDI-PubMed.29768713.s4.e4" e2="DDI-PubMed.29768713.s4.e4" /><pair ddi="false" e1="DDI-PubMed.29768713.s4.e4" e2="DDI-PubMed.29768713.s4.e5" /><pair ddi="false" e1="DDI-PubMed.29768713.s4.e4" e2="DDI-PubMed.29768713.s4.e6" /><pair ddi="false" e1="DDI-PubMed.29768713.s4.e5" e2="DDI-PubMed.29768713.s4.e5" /><pair ddi="false" e1="DDI-PubMed.29768713.s4.e5" e2="DDI-PubMed.29768713.s4.e6" /></sentence><sentence text=" In addition, repaglinide was separately administered to the same subjects in study 2"><entity charOffset="14-25" id="DDI-PubMed.29768713.s5.e0" text="repaglinide" /></sentence><sentence text=" There were no major effects on the pharmacokinetics of CYP and transporter substrates, except for an approximate threefold increase in midazolam exposure after oral administration of BFE1224" /><sentence text=" The clinical DDIs of BFE1224 were mild for CYP3A and minor for other major CYPs (CYP1A2/2C8/2C9/2C19/2D6) as well as those of P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), organic anion transporting polypeptide (OATP) 1B1, and OATP1B3" /><sentence text="" /></document>